TScan Q3 net loss $35.7M; pauses solid tumor enrollment, advances heme pivotal trial

TScan Therapeutics, Inc.

2025-Q3 EPS reported -$0.82 revenue$7,758,000

Revenue $2.5M (up from $1.0M YoY); net loss $35.7M vs $29.9M; cash $184.5M funds into H2 2027.
FDA agreed on pivotal trial design for TSC-101 in AML/MDS; pivotal launch expected Q2 2026.
Strategic decision: prioritize heme program, pause PLEXI-T solid tumor enrollment; shift to in vivo engineering.
Plans to present updated ALLOHA heme data at ASH Dec 2025; two IND submissions for heme candidates in Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.